CN1220701C - 重组人外周淋巴组织趋化性细胞因子及其制备方法和用途 - Google Patents
重组人外周淋巴组织趋化性细胞因子及其制备方法和用途 Download PDFInfo
- Publication number
- CN1220701C CN1220701C CN 02141557 CN02141557A CN1220701C CN 1220701 C CN1220701 C CN 1220701C CN 02141557 CN02141557 CN 02141557 CN 02141557 A CN02141557 A CN 02141557A CN 1220701 C CN1220701 C CN 1220701C
- Authority
- CN
- China
- Prior art keywords
- slc
- recombinant human
- lymphoid tissue
- human peripheral
- cytokine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 210000003563 lymphoid tissue Anatomy 0.000 title claims description 32
- 238000000034 method Methods 0.000 title claims description 23
- 102000004127 Cytokines Human genes 0.000 title abstract description 4
- 108090000695 Cytokines Proteins 0.000 title abstract description 4
- 230000035605 chemotaxis Effects 0.000 title description 8
- 108010012236 Chemokines Proteins 0.000 claims abstract description 51
- 102000019034 Chemokines Human genes 0.000 claims abstract description 49
- 230000002093 peripheral effect Effects 0.000 claims abstract description 37
- 210000004027 cell Anatomy 0.000 claims abstract description 27
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 15
- 239000003814 drug Substances 0.000 claims abstract description 4
- 230000014509 gene expression Effects 0.000 claims description 20
- 230000003399 chemotactic effect Effects 0.000 claims description 14
- 239000012634 fragment Substances 0.000 claims description 14
- 230000008521 reorganization Effects 0.000 claims description 14
- 241000588724 Escherichia coli Species 0.000 claims description 12
- 230000000694 effects Effects 0.000 claims description 12
- 210000004698 lymphocyte Anatomy 0.000 claims description 12
- 241000894006 Bacteria Species 0.000 claims description 11
- 239000013604 expression vector Substances 0.000 claims description 10
- 230000000968 intestinal effect Effects 0.000 claims description 10
- 239000002773 nucleotide Substances 0.000 claims description 10
- 125000003729 nucleotide group Chemical group 0.000 claims description 10
- 238000002360 preparation method Methods 0.000 claims description 7
- 108020004705 Codon Proteins 0.000 claims description 6
- 238000013461 design Methods 0.000 claims description 6
- 108010076504 Protein Sorting Signals Proteins 0.000 claims description 5
- 238000003556 assay Methods 0.000 claims description 5
- 238000000746 purification Methods 0.000 claims description 5
- 238000011282 treatment Methods 0.000 claims description 5
- 239000000147 enterotoxin Substances 0.000 claims description 4
- 231100000655 enterotoxin Toxicity 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 2
- 238000000926 separation method Methods 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 abstract description 9
- 210000002751 lymph Anatomy 0.000 abstract 4
- 229940079593 drug Drugs 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 102100036846 C-C motif chemokine 21 Human genes 0.000 description 50
- 108020004414 DNA Proteins 0.000 description 22
- 230000009182 swimming Effects 0.000 description 21
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 14
- 230000003321 amplification Effects 0.000 description 14
- 239000000047 product Substances 0.000 description 13
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
- 210000001744 T-lymphocyte Anatomy 0.000 description 12
- 238000003199 nucleic acid amplification method Methods 0.000 description 12
- 239000013612 plasmid Substances 0.000 description 12
- 238000001556 precipitation Methods 0.000 description 12
- 108091008146 restriction endonucleases Proteins 0.000 description 11
- 210000003000 inclusion body Anatomy 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 239000012528 membrane Substances 0.000 description 8
- 239000000523 sample Substances 0.000 description 8
- 239000006228 supernatant Substances 0.000 description 8
- 238000013016 damping Methods 0.000 description 7
- 238000001962 electrophoresis Methods 0.000 description 7
- 239000012530 fluid Substances 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 210000004443 dendritic cell Anatomy 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 102100036301 C-C chemokine receptor type 7 Human genes 0.000 description 5
- 101000716065 Homo sapiens C-C chemokine receptor type 7 Proteins 0.000 description 5
- 238000005336 cracking Methods 0.000 description 5
- 230000000527 lymphocytic effect Effects 0.000 description 5
- 239000003550 marker Substances 0.000 description 5
- 238000004153 renaturation Methods 0.000 description 5
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 5
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 230000029087 digestion Effects 0.000 description 4
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 4
- 238000009169 immunotherapy Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- 238000001262 western blot Methods 0.000 description 4
- 102100036842 C-C motif chemokine 19 Human genes 0.000 description 3
- 108010082161 Chemokine CCL19 Proteins 0.000 description 3
- 108010083702 Chemokine CCL21 Proteins 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 3
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 3
- 238000001042 affinity chromatography Methods 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 239000012149 elution buffer Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000012264 purified product Substances 0.000 description 3
- 102000009410 Chemokine receptor Human genes 0.000 description 2
- 108050000299 Chemokine receptor Proteins 0.000 description 2
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000003960 Ligases Human genes 0.000 description 2
- 108090000364 Ligases Proteins 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 241000156302 Porcine hemagglutinating encephalomyelitis virus Species 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 239000013504 Triton X-100 Substances 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000005018 casein Substances 0.000 description 2
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 2
- 235000021240 caseins Nutrition 0.000 description 2
- 230000012292 cell migration Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000006073 displacement reaction Methods 0.000 description 2
- 239000013613 expression plasmid Substances 0.000 description 2
- 238000013467 fragmentation Methods 0.000 description 2
- 238000006062 fragmentation reaction Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 102000006495 integrins Human genes 0.000 description 2
- 108010044426 integrins Proteins 0.000 description 2
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 230000010355 oscillation Effects 0.000 description 2
- 229920000515 polycarbonate Polymers 0.000 description 2
- 239000004417 polycarbonate Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 102220023257 rs387907546 Human genes 0.000 description 2
- 102220023258 rs387907548 Human genes 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 229960001866 silicon dioxide Drugs 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 230000004862 vasculogenesis Effects 0.000 description 2
- 210000000264 venule Anatomy 0.000 description 2
- 101150072531 10 gene Proteins 0.000 description 1
- 108010022579 ATP dependent 26S protease Proteins 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 102100036850 C-C motif chemokine 23 Human genes 0.000 description 1
- 101100008046 Caenorhabditis elegans cut-2 gene Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 108091006027 G proteins Proteins 0.000 description 1
- 102000030782 GTP binding Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins 0.000 description 1
- 108010093488 His-His-His-His-His-His Proteins 0.000 description 1
- 101000713081 Homo sapiens C-C motif chemokine 23 Proteins 0.000 description 1
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 108010039491 Ricin Proteins 0.000 description 1
- 239000012505 Superdex™ Substances 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 239000006035 Tryptophane Substances 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 238000005267 amalgamation Methods 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000006023 anti-tumor response Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000012148 binding buffer Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 239000002975 chemoattractant Substances 0.000 description 1
- 238000011097 chromatography purification Methods 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 210000000222 eosinocyte Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 229960000789 guanidine hydrochloride Drugs 0.000 description 1
- 102000057593 human F8 Human genes 0.000 description 1
- 210000003917 human chromosome Anatomy 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000036046 immunoreaction Effects 0.000 description 1
- 229960001438 immunostimulant agent Drugs 0.000 description 1
- 239000003022 immunostimulating agent Substances 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 230000022288 lymphocyte chemotaxis Effects 0.000 description 1
- 210000005210 lymphoid organ Anatomy 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000005499 meniscus Effects 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000007500 overflow downdraw method Methods 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 229920002704 polyhistidine Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 238000011112 process operation Methods 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 229940047431 recombinate Drugs 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 210000005212 secondary lymphoid organ Anatomy 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 239000012137 tryptone Substances 0.000 description 1
- 229960004799 tryptophan Drugs 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Images
Landscapes
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims (11)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 02141557 CN1220701C (zh) | 2002-09-02 | 2002-09-02 | 重组人外周淋巴组织趋化性细胞因子及其制备方法和用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 02141557 CN1220701C (zh) | 2002-09-02 | 2002-09-02 | 重组人外周淋巴组织趋化性细胞因子及其制备方法和用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1480465A CN1480465A (zh) | 2004-03-10 |
CN1220701C true CN1220701C (zh) | 2005-09-28 |
Family
ID=34147806
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 02141557 Expired - Fee Related CN1220701C (zh) | 2002-09-02 | 2002-09-02 | 重组人外周淋巴组织趋化性细胞因子及其制备方法和用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1220701C (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017214939A1 (zh) * | 2016-06-16 | 2017-12-21 | 毛侃琅 | 提升 ccr7 基因表达水平的慢病毒表达载体及其应用 |
-
2002
- 2002-09-02 CN CN 02141557 patent/CN1220701C/zh not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CN1480465A (zh) | 2004-03-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1217956C (zh) | 可溶性单链t细胞受体蛋白 | |
CN1104217A (zh) | 具有t细胞辅助活性的肽类 | |
CN1177982A (zh) | 作为融合蛋白的异源抗原的表达系统 | |
CN1198929C (zh) | 抗α/β干扰素受体的抗体 | |
CN1214050A (zh) | 人肿瘤坏死因子δ和ε | |
CN1902221A (zh) | 基于中和表位的生长增强疫苗 | |
CN1214052A (zh) | 分离的二聚体成纤维细胞激活蛋白α及其用途 | |
CN1194000A (zh) | 增强保护性免疫应答的方法 | |
CN1149887A (zh) | 刺激和增强保护性免疫反应和il-12产生的化合物和方法 | |
CN1105725C (zh) | Fas/ap01受体功能的调节物 | |
CN1604965A (zh) | 生长激素融合蛋白 | |
CN1322213A (zh) | 炎症疾病的治疗 | |
CN1436246A (zh) | 制备具有生理活性的il-18多肽的方法 | |
CN1220701C (zh) | 重组人外周淋巴组织趋化性细胞因子及其制备方法和用途 | |
CN1245533A (zh) | 哺乳动物趋化因子 | |
CN87108308A (zh) | 新的多肽及其生产 | |
CN1286976C (zh) | α/β-干扰素结合蛋白,制法及用途 | |
CN1157570A (zh) | 化学药物向特定细胞的细胞内载运 | |
CN1192751A (zh) | 单核细胞趋化蛋白-4 | |
CN1597697A (zh) | 一种人的甲状旁腺素1-34肽相关肽-Pro-Pro-[Arg11]]hPTH(1-34)-Pro-Pro | |
CN1206239C (zh) | 环己肽及其混合物,其制备方法及其用途 | |
CN1313494C (zh) | 一种具有促增长作用的融合蛋白及其编码基因与应用 | |
CN1020923C (zh) | 利用dna重组技术生产抑制素的方法 | |
CN1007906B (zh) | 高纯度蛋白质的制备及其应用 | |
CN1229140C (zh) | 一种靶向防龋dna疫苗及制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: HONGYE INTERNATIONAL INVESTMENT GROUP CO., LTD. Free format text: FORMER OWNER: INST. OF GENETICS + DEVELOPMENT BIOLOGY, CHINESE ACADEMY OF SCIENCES Effective date: 20120625 Free format text: FORMER OWNER: BEIJING ANBOTE GENE ENGINEERING CO., LTD. Effective date: 20120625 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 100101 CHAOYANG, BEIJING TO: 016000 WUHAI, INNER MONGOLIA AUTONOMOUS REGION |
|
TR01 | Transfer of patent right |
Effective date of registration: 20120625 Address after: 016000 the Inner Mongolia Autonomous Region Wuhai city Haibowan District Kapoor third factory (old north ditch) Patentee after: HONGYE INTERNATIONAL INVESTMENT GROUP Co.,Ltd. Address before: 100101 Beijing City, Datun Road, building 917 Co-patentee before: BEIJING ABT GENETIC ENGINEERING TECHNOLOGY Co.,Ltd. Patentee before: INSTITUTE OF GENETICS AND DEVELOPMENTAL BIOLOGY, CHINESE ACADEMY OF SCIENCES |
|
ASS | Succession or assignment of patent right |
Owner name: HONGYE XINCHUANG ANTIBODY TECHNOLOGY CO., LTD. Free format text: FORMER OWNER: HONGYE INTERNATIONAL INVESTMENT GROUP CO., LTD. Effective date: 20121015 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 016000 WUHAI, INNER MONGOLIA AUTONOMOUS REGION TO: 102206 CHANGPING, BEIJING |
|
TR01 | Transfer of patent right |
Effective date of registration: 20121015 Address after: 102206, innovation building C-301, 29 life road, Beijing, Changping District Patentee after: HONGYE INNOVATIVE ANTIBODY TECHNOLOGIES CO.,LTD. Address before: 016000 the Inner Mongolia Autonomous Region Wuhai city Haibowan District Kapoor third factory (old north ditch) Patentee before: HONGYE INTERNATIONAL INVESTMENT GROUP Co.,Ltd. |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Recombinded chemotaxis cytokine of human cirumferential lymphatic tissue as well as its preparing method and usage Effective date of registration: 20160824 Granted publication date: 20050928 Pledgee: Huachen Trust Co Ltd Pledgor: HONGYE INNOVATIVE ANTIBODY TECHNOLOGIES CO.,LTD. Registration number: 2016990000738 |
|
PLDC | Enforcement, change and cancellation of contracts on pledge of patent right or utility model | ||
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20050928 Termination date: 20210902 |